GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALG1L | SNV | Missense_Mutation | novel | c.363A>T | p.Glu121Asp | p.E121D | | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ALG1L | SNV | Missense_Mutation | rs371544045 | c.149N>T | p.Thr50Met | p.T50M | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALG1L | SNV | Missense_Mutation | novel | c.609G>T | p.Gln203His | p.Q203H | | protein_coding | deleterious_low_confidence(0.01) | benign(0.102) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG1L | SNV | Missense_Mutation | rs139400046 | c.571N>A | p.Pro191Thr | p.P191T | | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ALG1L | SNV | Missense_Mutation | novel | c.73G>A | p.Ala25Thr | p.A25T | | protein_coding | tolerated(0.1) | possibly_damaging(0.584) | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ALG1L | SNV | Missense_Mutation | novel | c.253T>C | p.Ser85Pro | p.S85P | | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG1L | SNV | Missense_Mutation | novel | c.445N>G | p.Leu149Val | p.L149V | | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-DD-AAVR-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ALG1L | SNV | Missense_Mutation | rs373951263 | c.121N>A | p.Glu41Lys | p.E41K | | protein_coding | tolerated(0.61) | benign(0.22) | TCGA-55-7911-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALG1L | SNV | Missense_Mutation | rs770698301 | c.587N>A | p.Arg196His | p.R196H | | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-MF-A522-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
ALG1L | SNV | Missense_Mutation | rs368430945 | c.119N>A | p.Arg40His | p.R40H | | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-CQ-A4C9-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |